Scientists probe gene changes behind RLS drug side effects

NCT ID NCT06726785

Recruiting now Knowledge-focused Sponsor: HBC Immunology Inc Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tracks gene changes in people with Restless Legs Syndrome who take dopamine agonists for different lengths of time. Researchers will collect nasal swabs from 50 participants—some new to the drugs, others on them for 6+ months—to see how key genes change. The goal is to better understand augmentation syndrome, a condition where symptoms worsen over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dopamine agonists (pramipexole, ropinirole, rotigotine, apomorphine, bromocriptine)
What this could lead to: If successful, this research could help explain why some RLS patients get worse over time with dopamine agonists, potentially pointing toward safer treatment strategies.
What could go wrong: This is a small, early observational study (50 people) measuring gene expression, not a treatment trial. It may not find clear patterns or lead directly to new treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESTLESS LEG SYNDROME (RLS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neurologic Manifestations restless legs syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESTLESS LEG SYNDROME (RLS)

Contacts and locations

Locations

Alethios Inc
RECRUITING

San Francisco, California, 94109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.